COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naïve" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Haemato oncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Haemato oncology University Hospital Ostrava Ostrava Czech Republic

Department of Haematology and Oncology University Hospital Pilsen Pilsen Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic

Department of Hematology Silesian Hospital in Opava Opava Czech Republic

Department of Internal Medicine and Haematology University Hospital Královské Vinohrady and 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Internal Medicine Hematology and Oncology Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Chen P, Nirula A, Heller B, et al. SARS‐CoV‐2 neutralizing antibody LY‐CoV555 in outpatients with Covid‐19. N Engl J Med. 2021;384(3):229‐237. PubMed PMC

Weinreich DM, Sivapalasingam S, Norton T, et al. REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19. N Engl J Med. 2021;384(3):238‐251. PubMed PMC

Ganesh R, Pawlowski CF, O’Horo JC, et al. Intravenous bamlanivimab use associates with reduced hospitalization in high‐risk patients with mild to moderate COVID‐19. J Clin Invest. 2021;131(19):e151697. PubMed PMC

Verderese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID‐19: a real‐world experience. Clin Infect Dis. 2021:ciab579. PubMed PMC

Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881‐2892. PubMed PMC

Pagano L, Salmanton‐García J, Marchesi F, et al. COVID‐19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. PubMed PMC

Dhand A, Lobo SA, Wolfe K, Feola N, Nabors C. Bamlanivimab for treatment of COVID‐19 in solid organ transplant recipients: early single‐center experience. Clin Transpl. 2021;35(4):e14245. PubMed PMC

Dhand A, Lobo SA, Wolfe K, et al. Casirivimab‐imdevimab for treatment of COVID‐19 in solid organ transplant recipients: an early experience. Transplantation. 2021;105(7):e68‐e69. PubMed

Puing AG, Ho S, Frankel P, et al. SARS‐CoV‐2 specific monoclonal antibody for the treatment of mild‐to‐moderate COVID‐19 in cancer patients: a single‐center experience. J Infect Dis. 2021:jiab406. PubMed PMC

Saultier P, Ninove L, Szepetowski S, et al. Monoclonal antibodies for the treatment of COVID‐19 in a patient with high‐risk acute leukaemia. Br J Haematol. 2021;196. 10.1111/bjh.17756 PubMed DOI PMC

Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid‐19. N Engl J Med. 2020;383(18):1757‐1766. PubMed

Chen RE, Winkler ES, Case JB, et al. In vivo monoclonal antibody efficacy against SARS‐CoV‐2 variant strains. Nature. 2021;596(7870):103‐108. PubMed PMC

Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era

Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies-The First Single-Centre Experience from the Czech Republic